A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males
NCT ID: NCT01506752
Last Updated: 2012-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2011-07-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect
NCT00807118
Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects
NCT01595425
Donepezil 10 mg Tablets Under Fed Conditions
NCT01439243
Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
NCT01389609
A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants
NCT05877222
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
E2020 improved 10 mg without water
Donepezil Hydrochloride
improved orally disintegrating E2020 10 mg tablet without water.
E2020 current 10 mg without water
Donepezil Hydrochloride
current orally disintegrating E2020 10 mg tablet without water.
E2020 improved 10 mg with water
Donepezil Hydrochloride
improved orally disintegrating E2020 10 mg tablet with water.
E2020 current 10 mg with water
Donepezil Hydrochloride
current orally disintegrating E2020 10 mg tablet with water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Donepezil Hydrochloride
improved orally disintegrating E2020 10 mg tablet without water.
Donepezil Hydrochloride
current orally disintegrating E2020 10 mg tablet without water.
Donepezil Hydrochloride
improved orally disintegrating E2020 10 mg tablet with water.
Donepezil Hydrochloride
current orally disintegrating E2020 10 mg tablet with water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Those who provide consent by their own will.
2. Male subjects aged between ≥ 20 years and \< 45 years old at the time of obtaining informed consent and non-smoker (subjects who have not been smoking for at least 4 weeks prior to study treatment)
3. BMI at screening is 18.5 kg/m2 or above and less than 25.0 kg/m2
4. Those who are willing to and can comply with the conditions described in the study protocol.
Exclusion Criteria
1. Any significant medical illness that required intervention within 8 weeks before treatment, or any medical history of clinically significant infectious diseases within 4 weeks before treatment.
2. Those who had any psychiatric, GI tract, hepatic, renal, respiratory, endocrine, hematological, neurological, cardiovascular diseases or congenital metabolic disorders within 4 weeks before study drug administration that may have an impact on the evaluation of the drug.
3. Subjects who have any medical history of GI, hepatic, or renal surgery (e.g. excision of liver, kidney or GI tract) that may have an impact on pharmacokinetics of the drug.
4. Subjects who have any history of medically significant allergy to medications or foods, and those who currently have any symptoms of seasonal
5. Subjects whose weight changes were more than 10% from the screening phase to study drug administration.
6. Those with clinical abnormal symptoms, medical history of organ dysfunction, subjective symptoms, objective findings, vital signs, and abnormal EKG or clinical laboratory test values, which need medical intervention.
7. Corrected change in QT wave (QTc) interval of \> 450 msec with 12-lead EKG at screening or study drug administration.
8. Subjects who are positive for hepatitis B surface antigen (HBs antigen), hepatitis C (HCV) antibody, or serologic test for syphilis (STS).
9. Subjects who are suspected with or who has a history of drug or alcohol abuse, or positive urine screen for drugs of abuse or exhalation alcohol test at screening or baseline.
10. Subjects who consumed caffeine-containing food or beverages within 72 hours before study drug administration.
11. Exposure to any supplements or herbs (including Chinese medicine), or beverages (e.g. alcohol or grapefruit-containing beverages, within 2 weeks of study drug administration.
12. Exposure to St. John's wort containing medications within 4 weeks of study drug administration.
13. Use of any prescription drugs within 4 week before study drug administration.
14. Use of any OTC medications within 2 week before study drug administration.
15. Subjects who enrolled in another clinical trial and exposed to any investigational drug within 16 weeks of study enrollment.
16. Subjects who received blood infusion within 12 weeks, those who had blood drawn 400 mL or more within 12 weeks, 400 mL, or 200 mL or more within 4 weeks, or sampling of a component of the blood within 2 week of study drug administration.
17. Subjects who performed extreme exercises or exhausting labors (more than 1 hr/day or 5 day/week) within 2 weeks before hospitalization.
18. Any subject who, or whose partner, does not want to take highly reliable contraceptive measures until the end of the post-treatment examination.
19. Subjects who are inappropriate to participate in the study, as judged by the investigator or subinvestigator
20 Years
44 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hiroki Shimizu
Role: STUDY_DIRECTOR
Eisai Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sumida-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2020-J081-034
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.